JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.
Loding Loading ....

GenomeMe Lab Inc

1-3691 Viking Way, Richmond, Richmond, British Columbia, V6V2J6, Canada

Get Direction

Why Choose GenomeMe?

 
Wholesale Prices
Stringent Quality Control Processes
Satisfaction Guaranteed Advanced Technologies
 

Our Mission


To advance precision diagnostics through quality IHC antibodies.

Who We Are

GenomeMe Lab Inc. is a Vancouver-based biotech company specializing in mouse and rabbit IHC (immunohistochemistry) monoclonal antibodies for clinical diagnostic use. Since our inception in 2017, our goal has been to develop each of the 260+ clinical IHC antibodies in-house, making us the first and only institution to date to achieve this. We are on track to reach this R&D goal by the end of 2021 - hitting a monumental milestone in the history of our company’s development.

Because we develop and manufacture all of our antibodies in-house, we are able to offer our distributors, OEM partners, and valuable end user customers the best value and quality. GenomeMe Lab Inc. is rising to be a dominant player in diagnostic IHC applications, an increasingly essential part of future precision medicine technologies.

Certifications

ISO 13485:2016
Products manufactured under Quality Management System conforming with ISO 13485:2016 as certified by Intertek.
CE IVD
Our products are CE IVD Certified for diagnostic use.
NordiQC
External quality assessments by NordiQC, an international profiency testing program for diagnostic IHC.

Awards

13th Biggest Life Sciences Company, 2019

Technologies

qPCR
qPCR is the gold standard in diagnostics, providing rapid, specific, and sensitive detection.
Next Generation Sequencing
We combine hybridoma and Next Generation Sequencing technologies to successfully develop mouse and rabbit monoclonal antibodies for clinical applications.
Immunohistochemistry
Our immunohistochemistry staining and Microtome equipment enable us to rapidly screen, validate, and QC our molecular pathology portfolio.